A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib

NCT03804515 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
2
Enrollment
INDUSTRY
Sponsor class

Stopped COVID

Conditions

Interventions

Sponsor

Spectrum Pharmaceuticals, Inc